Pazopanib Oral Tablet [Votrient] — Competitive Intelligence Brief

Pazopanib Oral Tablet [Votrient] (Pazopanib Oral Tablet [Votrient]) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: tyrosine kinase inhibitor. Area: Oncology.

phase 3 tyrosine kinase inhibitor VEGFR, PDGFR, c-KIT Oncology Small molecule

Target snapshot

Pazopanib Oral Tablet [Votrient] (Pazopanib Oral Tablet [Votrient]) — Centre Leon Berard. Pazopanib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), and c-KIT.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pazopanib Oral Tablet [Votrient] TARGET	Pazopanib Oral Tablet [Votrient]	Centre Leon Berard	phase 3	tyrosine kinase inhibitor	VEGFR, PDGFR, c-KIT
Sunitinib + Capecitabine	Sunitinib + Capecitabine	Pfizer	phase 3	tyrosine kinase inhibitor, antimetabolite	VEGFR, PDGFR, c-KIT, thymidylate synthase
TQB2450+Anlotinib	TQB2450+Anlotinib	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	phase 3	Tyrosine kinase inhibitor	VEGFR, PDGFR, c-Kit
Inlyta	Axitinib	Pfizer	marketed	Receptor tyrosine kinase inhibitor	Vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, VEGFR-3	2012-01-01
Sunitinib (Sutent)	Sunitinib (Sutent)	Sponsor GmbH	marketed	Multi-targeted tyrosine kinase inhibitor	VEGFR, PDGFR, KIT, FLT3
pazopanib or guideline conform chemotherapy	pazopanib or guideline conform chemotherapy	GWT-TUD GmbH	marketed	Multi-targeted tyrosine kinase inhibitor	VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α, PDGFR-β, c-Kit
Icotinib plus WBRT	Icotinib plus WBRT	Betta Pharmaceuticals Co., Ltd.	marketed	EGFR tyrosine kinase inhibitor	EGFR (epidermal growth factor receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (tyrosine kinase inhibitor class)

1. Centre Leon Berard · 2 drugs in this class
2. Akeso · 1 drug in this class
3. Astex Pharmaceuticals, Inc. · 1 drug in this class
4. Chengdu Zenitar Biomedical Technology Co., Ltd · 1 drug in this class
5. Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
6. Jiangsu ShengDiYa Medicine Co., Ltd. · 1 drug in this class
7. Nanjing Leads Biolabs Co.,Ltd · 1 drug in this class
8. Ocular Therapeutix, Inc. · 1 drug in this class
9. Peking University Cancer Hospital & Institute · 1 drug in this class
10. Pfizer · 1 drug in this class